Watada H, Kaneko S, Komatsu M, et al. - In Japanese people with T2D, researchers conducted this 26-week, double-blind, multicentre, treat-to-target trial to test the effectiveness and safety of insulin degludec/liraglutide (IDegLira) vs 50 U insulin degludec (degludec) or less. For this investigation, Japanese people with T2D uncontrolled with basal or premix insulin (20–50 units) were randomised (1:1) to receive IDegLira or degludec both with metformin. The highest dose was 50 dose steps (IDegLira) or 50 units (degludec). A total of 210 Japanese people have been randomised to IDegLira or degludec and completion rates were 100% and 93%, respectively. Investigators found that mean change in body weight was –0.7 kg with IDegLira compared with 0.7 kg with degludec. According to findings, IDegLira gave superior HbA_1c decreases vs ≤ 50U degludec, with weight loss and comparable hypoglycaemia rates and no unforeseen safety or tolerability issues. For Japanese patients with T2D uncontrolled on basal or premixed insulin, this therapy could be an appealing alternative for intensification.